抗新型冠状病毒2019-nCoV新药的研发

2019年底，湖北武汉暴发了2019新型冠状病毒感染疾病（COVID-19），并快速在全国蔓延，且在多个国家发现病例。其感染病例和死亡病例在短时间内快速超过重症急性呼吸综合征（SARS），给中国带来了不可估量的损失。中国科研人员在短时间内，快速锁定病原体为2019-nCoV（或hCoV-19或SARS-CoV-2)，并且在不同层面开展了相关抗病毒药物的研发工作。本文介绍了抗2019-nCoV新药研发的现状。同时，鉴于突发病原体的药物研发过程相对迟缓，我们建议对于潜在流行可能性的病原体，其药物研发要具有前瞻性，国家层面要推进广谱药物的研发和临床试验，以应对可能出现的疫情风险。

Research and development of antiviral drugs against new coronavirus 2019-nCoV

At the end of 2019,an outbreak of 2019 new coronavirus infectious disease (COVID-19) in Wuhan spread rapidly in China and reported cases in other countries.The number of infected cases and deaths quickly exceeded Severe Acute Respiratory Syndrome (SARS) in a short period of time,resulting in incalculable losses to China.Chinese researchers have quickly identified the pathogen,2019-nCoV (or SARS-CoV-2 or HCoV-19) and carried out the research and development of antiviral drugs at different levels.This article briefly reviews the current advancement of research and development of new therapeutics against 2019-nCoV infection.Given that the progress of research and development of antiviral drugs against the emerging and reemerging pathogens is relatively backwarded,we suggest that the research and development of antivirals against pathogens with pandemic or epidemic potential should be carried out in advance before the occurrence of the outbreaks. At the national level,we should promote the research and development of broad-spectrum antivirals and clinical trials to combat the pathogens with epidemic risk.